DK3635102T3 - B4galt1-varianter og anvendelser deraf - Google Patents

B4galt1-varianter og anvendelser deraf

Info

Publication number
DK3635102T3
DK3635102T3 DK18733472.7T DK18733472T DK3635102T3 DK 3635102 T3 DK3635102 T3 DK 3635102T3 DK 18733472 T DK18733472 T DK 18733472T DK 3635102 T3 DK3635102 T3 DK 3635102T3
Authority
DK
Denmark
Prior art keywords
b4galt1
variants
b4galt1 variants
Prior art date
Application number
DK18733472.7T
Other languages
Danish (da)
English (en)
Inventor
May Montasser
Hout Cristopher Van
Alan Shuldiner
Giusy Della Gatta
Matthew Healy
Marja Puurunen
Original Assignee
Regeneron Pharma
Univ Maryland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma, Univ Maryland filed Critical Regeneron Pharma
Application granted granted Critical
Publication of DK3635102T3 publication Critical patent/DK3635102T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • C12Y204/01133—Xylosylprotein 4-beta-galactosyltransferase (2.4.1.133)

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Enzymes And Modification Thereof (AREA)
DK18733472.7T 2017-06-05 2018-06-04 B4galt1-varianter og anvendelser deraf DK3635102T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762515140P 2017-06-05 2017-06-05
US201762550161P 2017-08-25 2017-08-25
US201862659344P 2018-04-18 2018-04-18
PCT/US2018/035806 WO2018226560A1 (en) 2017-06-05 2018-06-04 B4galt1 variants and uses thereof

Publications (1)

Publication Number Publication Date
DK3635102T3 true DK3635102T3 (da) 2025-10-27

Family

ID=62705750

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18733472.7T DK3635102T3 (da) 2017-06-05 2018-06-04 B4galt1-varianter og anvendelser deraf

Country Status (14)

Country Link
US (2) US10738284B2 (cg-RX-API-DMAC7.html)
EP (1) EP3635102B1 (cg-RX-API-DMAC7.html)
JP (2) JP7661009B2 (cg-RX-API-DMAC7.html)
KR (1) KR102624979B1 (cg-RX-API-DMAC7.html)
CN (1) CN110997906B (cg-RX-API-DMAC7.html)
AU (1) AU2018282072B2 (cg-RX-API-DMAC7.html)
CA (1) CA3065938A1 (cg-RX-API-DMAC7.html)
DK (1) DK3635102T3 (cg-RX-API-DMAC7.html)
ES (1) ES3049196T3 (cg-RX-API-DMAC7.html)
FI (1) FI3635102T3 (cg-RX-API-DMAC7.html)
IL (1) IL271073B2 (cg-RX-API-DMAC7.html)
MX (1) MX2019014661A (cg-RX-API-DMAC7.html)
SG (1) SG11201911597YA (cg-RX-API-DMAC7.html)
WO (1) WO2018226560A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3635102B1 (en) 2017-06-05 2025-08-13 Regeneron Pharmaceuticals, Inc. B4galt1 variants and uses thereof
IL295080A (en) * 2020-03-04 2022-09-01 Regeneron Pharma A rodent model of b4galt1-mediated functions
WO2023232983A1 (en) 2022-06-01 2023-12-07 E-Therapeutics Plc Inhibitors of expression and/or function
AU2023390632A1 (en) * 2022-12-09 2025-07-10 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of cardiovascular disease
CN115960926A (zh) * 2022-12-30 2023-04-14 南方科技大学 一种mRNA及含有mRNA的药物
WO2025021989A1 (en) * 2023-07-27 2025-01-30 E-Therapeutics Plc Inhibitors of expression and/or function

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5294533A (en) 1988-07-05 1994-03-15 Baylor College Of Medicine Antisense oligonucleotide antibiotics complementary to the macromolecular synthesis operon, methods of treating bacterial infections and methods for identification of bacteria
US5135917A (en) 1990-07-12 1992-08-04 Nova Pharmaceutical Corporation Interleukin receptor expression inhibiting antisense oligonucleotides
US5271941A (en) 1990-11-02 1993-12-21 Cho Chung Yoon S Antisense oligonucleotides of human regulatory subunit RI.sub.α of cAMP-dependent protein kinases
US5786138A (en) 1993-01-29 1998-07-28 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Hyperstabilizing antisense nucleic acid binding agents
AU693097B2 (en) 1993-06-04 1998-06-25 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Method for treating kaposi's sarcoma with antisense oligonucleotides
US5578716A (en) 1993-12-01 1996-11-26 Mcgill University DNA methyltransferase antisense oligonucleotides
US5641754A (en) 1994-01-10 1997-06-24 The Board Of Regents Of The University Of Nebraska Antisense oligonucleotide compositions for selectively killing cancer cells
EP0775204A1 (en) 1994-08-09 1997-05-28 Novartis AG Antitumor antisense oligonucleotides
US5856103A (en) 1994-10-07 1999-01-05 Board Of Regents The University Of Texas Method for selectively ranking sequences for antisense targeting
US5994320A (en) 1995-02-06 1999-11-30 Regents Of The University Of Minnesota Antisense oligonucleotides and methods for treating central nervous system tumors
IT1275862B1 (it) 1995-03-03 1997-10-24 Consiglio Nazionale Ricerche Trascritto antisenso associato ad alcuni tipi di cellule tumorali ed oligodeossinucleotidi sintetici utili nella diagnosi e nel trattamento
US6040296A (en) 1995-06-07 2000-03-21 East Carolina University Specific antisense oligonucleotide composition & method for treatment of disorders associated with bronchoconstriction and lung inflammation
WO1997014709A1 (en) 1995-10-13 1997-04-24 F. Hoffmann-La Roche Ag Antisense oligomers
JPH11507245A (ja) 1995-11-21 1999-06-29 アイシーエヌ・ファーマシューティカルズ・インコーポレイテッド Ｉｌ―８およびｉｌ―８受容体に対するアンチセンスオリゴヌクレオチドによる睡瘍増殖の阻害
AU708535B2 (en) 1996-02-15 1999-08-05 Cleveland Clinic Foundation, The RNase L activators and antisense oligonucleotides effective to treat RSV infections
US5955590A (en) 1996-07-15 1999-09-21 Worcester Foundation For Biomedical Research Conjugates of minor groove DNA binders with antisense oligonucleotides
US6046004A (en) 1997-02-27 2000-04-04 Lorne Park Research, Inc. Solution hybridization of nucleic acids with antisense probes having modified backbones
JPH1142091A (ja) 1997-07-25 1999-02-16 Toagosei Co Ltd アンチセンス核酸化合物
US6046319A (en) 1997-10-22 2000-04-04 University Technologies International, Inc. Antisense oligodeoxynucleotides regulating expression of TNF-α
US6007995A (en) 1998-06-26 1999-12-28 Isis Pharmaceuticals Inc. Antisense inhibition of TNFR1 expression
US6013522A (en) 1999-02-23 2000-01-11 Isis Pharmaceuticals Inc. Antisense inhibition of human Smad1 expression
US6025198A (en) 1999-06-25 2000-02-15 Isis Pharmaceuticals Inc. Antisense modulation of Ship-2 expression
US6033910A (en) 1999-07-19 2000-03-07 Isis Pharmaceuticals Inc. Antisense inhibition of MAP kinase kinase 6 expression
CN100575485C (zh) 2002-01-23 2009-12-30 犹他大学研究基金会 使用锌指核酸酶的定向染色体诱变
EP2368982A3 (en) 2002-03-21 2011-10-12 Sangamo BioSciences, Inc. Methods and compositions for using zinc finger endonucleases to enhance homologous recombination
JP2006502748A (ja) 2002-09-05 2006-01-26 カリフォルニア インスティテュート オブ テクノロジー 遺伝子ターゲッティングを誘発するキメラヌクレアーゼの使用方法
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US8409861B2 (en) 2003-08-08 2013-04-02 Sangamo Biosciences, Inc. Targeted deletion of cellular DNA sequences
US20080299042A1 (en) 2004-04-30 2008-12-04 Biogen Idec Ma Inc. Membrane Associated Molecules
US7374927B2 (en) 2004-05-03 2008-05-20 Affymetrix, Inc. Methods of analysis of degraded nucleic acid samples
EP1789095A2 (en) 2004-09-16 2007-05-30 Sangamo Biosciences Inc. Compositions and methods for protein production
US8512991B2 (en) * 2007-08-22 2013-08-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Beta 1,4-galactosyltransferases with altered donor and acceptor specificities, compositions and methods of use
WO2009102820A2 (en) * 2008-02-11 2009-08-20 Government Of The U.S A., As Represented By The Secretary, Department Of Health And Human Services Modified sugar substrates and methods of use
US20110239315A1 (en) 2009-01-12 2011-09-29 Ulla Bonas Modular dna-binding domains and methods of use
US8772008B2 (en) 2009-05-18 2014-07-08 Sangamo Biosciences, Inc. Methods and compositions for increasing nuclease activity
HUE041436T2 (hu) 2009-12-10 2019-05-28 Univ Minnesota Tal-effektor-közvetített DNS-módosítás
GB201000688D0 (en) * 2010-01-15 2010-03-03 Diagenic Asa Product and method
WO2011145121A1 (en) 2010-05-18 2011-11-24 Scatolificio Mogliani S.N.C. Di Mogliani Mauro E Andrea Cardboard box for stable stacking with other identical specimens
RU2444378C1 (ru) 2010-09-06 2012-03-10 Олег Германович Макеев Способ лечения коронарной недостаточности при моделируемой ишемии миокарда
WO2013176772A1 (en) 2012-05-25 2013-11-28 The Regents Of The University Of California Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
CN110643600A (zh) 2012-10-23 2020-01-03 基因工具股份有限公司 用于切割靶dna的系统及其用途
LT3138910T (lt) 2012-12-06 2017-11-10 Sigma-Aldrich Co. Llc Crispr pagrįstas genomo modifikavimas ir reguliavimas
EP2921557B1 (en) 2012-12-12 2016-07-13 The Broad Institute, Inc. Engineering of systems, methods and optimized guide compositions for sequence manipulation
WO2014131833A1 (en) 2013-02-27 2014-09-04 Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) Gene editing in the oocyte by cas9 nucleases
KR102271292B1 (ko) 2013-03-15 2021-07-02 더 제너럴 하스피탈 코포레이션 Rna-안내 게놈 편집의 특이성을 증가시키기 위한 rna-안내 foki 뉴클레아제(rfn)의 용도
CN115261411A (zh) 2013-04-04 2022-11-01 哈佛学院校长同事会 利用CRISPR/Cas系统的基因组编辑的治疗性用途
US20140356956A1 (en) 2013-06-04 2014-12-04 President And Fellows Of Harvard College RNA-Guided Transcriptional Regulation
EP3635102B1 (en) 2017-06-05 2025-08-13 Regeneron Pharmaceuticals, Inc. B4galt1 variants and uses thereof

Also Published As

Publication number Publication date
US10738284B2 (en) 2020-08-11
IL271073B2 (en) 2025-10-01
FI3635102T3 (fi) 2025-10-28
SG11201911597YA (en) 2020-01-30
CA3065938A1 (en) 2018-12-13
EP3635102A1 (en) 2020-04-15
JP2020527329A (ja) 2020-09-10
RU2019144018A3 (cg-RX-API-DMAC7.html) 2022-03-04
JP2023113657A (ja) 2023-08-16
IL271073A (en) 2020-01-30
US20200399617A1 (en) 2020-12-24
KR102624979B1 (ko) 2024-01-16
EP3635102B1 (en) 2025-08-13
JP7661009B2 (ja) 2025-04-14
US20180346888A1 (en) 2018-12-06
WO2018226560A1 (en) 2018-12-13
AU2018282072B2 (en) 2024-06-27
IL271073B1 (en) 2025-06-01
MX2019014661A (es) 2020-07-29
RU2019144018A (ru) 2021-07-09
ES3049196T3 (en) 2025-12-15
CN110997906B (zh) 2024-05-07
AU2018282072A1 (en) 2020-01-16
CN110997906A (zh) 2020-04-10
US12480103B2 (en) 2025-11-25
KR20200024772A (ko) 2020-03-09

Similar Documents

Publication Publication Date Title
IL293377A (en) Hsd17b13 variants and uses thereof
DK3610005T3 (da) Peptidligase og anvendelse deraf
DK3448386T3 (da) Isoquinolin-3-ylcarboxamider og fremstilling og anvendelse deraf
DK3411398T3 (da) Målrettede terapeutiske midler og anvendelse heraf
DK3668512T3 (da) Pyruvatkinasemodulatorer og anvendelse deraf
DK3485010T3 (da) Bacillus cibi-dnase-varianter og anvendelser deraf
DK3368534T3 (da) Valbenazin-ditosylat og polymorfer deraf
DK3559227T3 (da) Proteasevarianter og anvendelser deraf
DK3452463T3 (da) Amidsubstituerede pyridinyltriazolderivater og anvendelser deraf
DK3283106T3 (da) Terapeutiske antistoffer og anvendelser deraf
DK3268470T3 (da) Transposasepolypeptider og anvendelser deraf
DK3218358T3 (da) Ifluorometyl-aminopyridiner og difluorometyl-aminopyrimidiner
DK3269809T3 (da) MODIFICERET AMINOACYL-tRNA-SYNTETASE OG ANVENDELSE DERAF
DK3368655T3 (da) Forbedret proteinekspression og fremgangsmåder dertil
DK3236991T3 (da) Fgf21-derivater og anvendelser deraf
DK3603620T3 (da) Liposomsammensætning og farmaceutisk sammensætning
DK3128005T3 (da) Sirp-alfa-variantkonstruktioner og anvendelser deraf
DK3161139T3 (da) Tlr-4-specifikke aptamerer og anvendelser heraf
DK3209773T3 (da) Prolintolerante tripeptidylpeptidaser og anvendelser deraf
DK3490988T3 (da) Ny forbindelse og fremgangsmåde
DK3384079T3 (da) Fibrøs konstruktion og fremgangsmåder i forbindelse hermed
DK3265641T3 (da) Stigørenhed og fremgangsmåde
DK3692009T3 (da) Biocementationsfremgangsmåde og system
DK3635102T3 (da) B4galt1-varianter og anvendelser deraf
DK3621694T3 (da) Lrrc33-inhibitorer og anvendelse heraf